Research Projects & Grants

For Profit Organization

• A sample collection study to validate the astute medical NephroCheck test in critically ill subjects at risk for acute kidney injury, Role: Investigator, Astute Medical, Inc, (06/2012 - 06/2013) Status: Completed
• OASIS: A phase 2/3 randomized, double-blind, placebo-controlled, study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis, Role: PI, Agennix, Inc., (05/2012 - 05/2013) Status: Completed
• Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock, Role: PI, Eli Lilly & Co., (09/2011 - 09/2012) Status: Completed
• Portable Burn Debridement Laser Demonstration Program (PBDL), Role: Principal Investigator, Kelly Space & Technology, Inc., (01/2011 - 07/2012) Status: Closed
• A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis, protocol LF-0801, Role: PI, Agennix, Inc., (03/2009 - 03/2010) Status: Completed
• A phase 2 study to evaluate dose and duration of treatment of drotrecogin alfa (activated) using serial measurements of protein C in patients with severe and multiple organ dysfunctions, Role: PI, Eli Lilly & Co., (11/2008 - 11/2009) Status: Completed
• Comparison of venous oxygen saturation from pulse oximetry waveform analysis and central venous catheter, Role: Investigator, Edwards Lifesciences, (05/2006 - 05/2007) Status: Completed
• A prospective, randomized, double-blind, placebo controlled, dose ranging, multi-center study of the safety and efficacy of three days continuous intravenous infusion of GR270773 in the treatment of suspected or confirmed gram-negative severe sepsis in adults, Role: PI, GlaxoSmithKline, (07/2005 - 07/2006) Status: Completed
• A randomized, double-blind, placebo-controlled trial of prophylactic heparin in patients with severe sepsis and higher disease severity who are undergoing treatment with Drotrecogin Alfa (activated), Role: PI, Eli Lilly & Co., (12/2004 - 12/2005) Status: Completed
• A randomized, double-blind, placebo-controlled trial of prophylactic heparin in patients with severe sepsis and higher disease severity who are undergoing treatment with Drotrecogin Alfa (activated), Eli Lilly & Co., (01/2003 - 06/2004) Status: Closed
• An open-label study of recombinant human activated protein C in severe sepsis: a Phase III-B clinical trial., Role: PI, Eli Lilly & Co., (05/2001 - 05/2002) Status: Completed
• Multicenter study to evaluate the safety and efficacy of levofloxacin 500 mg., once daily, in treatment of community-acquired pneumonia in adults (CAPSS-043), Role: Investigator, Ortho-McNeil Pharmaceutical, (10/1999 - 10/2000) Status: Completed
• A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging evaluation of the safety and efficacy of a-hANP infusion (Carperitide for injection: SUN 4936) in patients with acute respiratory distress syndrome (ARDS) - Amendment 5., Role: PI, Suntory Pharmaceuticals, Inc., Status: Completed

Internal

• Registry for patients with sepsis presenting to the Emergency Department, Role: Investigator, LLU Dept. of Emergency Medicine, (11/2014 - 11/2015) Status: Completed
• Antibiotic prophylaxis in hospitalized patients with end stage liver disease (model for end stage liver disease score >30), Role: Investigator, LLU Dept. of Medicine, (11/2014 - 11/2015) Status: Completed
• Hyperbaric oxygen therapy in critically ill patients: a retrospective chart review, Role: Investigator, LLU Dept. of Medicine, (07/2014 - 07/2015) Status: Completed
• Fluctuations in blood glucose levels during hyperbaric oxygen therapy, Role: Investigator, LLUMC - Respiratory Care, (07/2014 - 07/2015) Status: Completed
• Angiogenesis: mechanisms in normoxia and hyperoxia, Role: Other (Specify), LLU - GRASP, (04/2014 - 04/2017) Status: Closed
• Hyperbaric oxygen therapy (HBOT) in the medical treatment of soft tissue radiation damage (STRD) and osteoradionecrosis (ORN): a retrospective study, Role: PI, LLU Dept. of Medicine, (03/2010) Status: Completed
• The role of nitric oxide in septic shock and increasing the rate of infection in decompensated cirrhotic patients, Role: Investigator, LLU Dept. of Medicine, (02/2009 - 02/2010) Status: Completed
• Takayasu's arteritis: a retrospective review and case report, Role: PI, LLU Dept. of Medicine, (02/2008 - 02/2009) Status: Completed
• Hyperbaric oxygen therapy in critically ill patients. A retrospective 25 year chart review., Role: PI, LLU Dept. of Medicine, (12/2007) Status: Completed
• Is hyperbaric oxygen therapy safe in critically ill pediatric patients?, Role: PI, LLU School of Medicine, (08/2007) Status: Completed
• The effect of a 3-channel electrode array, local heat and hyperabic oxygen therapy on healing of chronic wounds, Role: Investigator, LLU Dept. of Physical Therapy, (06/2007 - 06/2008) Status: Completed
• Biopotentials and healing, Role: Investigator, LLU School of Allied Health Professionals, (11/2004 - 11/2005) Status: Completed
• Rhinocerebral mucormycosis and hyperbaric oxygen therapy: a 20 year experience, Role: Investigator, LLU Dept. of Surgery, (03/2004) Status: Completed
• A double blind, randomized, placebo controlled study of inhaled nitric oxide in the treatment of Acute Respiratory Distress Syndrome (ARDS), Role: PI, LLU Dept. of Medicine, (12/1998 - 12/1999) Status: Completed
• International study of mechanical ventilation, Role: PI, Loma Linda University Medical Center, (02/1998) Status: Completed
• Inhaled nitric oxide for single patient emergency use, Role: Investigator, LLU Dept. of Surgery, Status: Completed